HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.26) - Policy Trend, Aier Eye Hospital, Hospital Project Construction

Jafron Biomedical (300529CH) 22H1- Possibility of Logic Reversal and Upside Potential of Stock Price

CanSino Biologics (6185.HK/688185.CH) 2022H1 - It's Too Early to Be Completely Bearish on CanSino

Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Still a “Safe Play” Despite Growth Slowdown

Wuxi Biologics (2269.HK) 2022H1 - Hard to Achieve V-Share Rebound

BeiGene (6160.HK/BGNE.US) 22H1- It Is an Indisputable Fact that BeiGene Is Difficult to Make Profits

WuXi AppTec (603259.CH/2359.HK) 2022H1 - The Concerns Behind and the Outlook

Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics / Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

<ul>
<li>Mindray withstood the negative impact of pandemic/lockdown and continued to achieve solid growth in 2022H1 amid China's “new infrastructure”  projects and the recovery of overseas demand for routine medical care.</li>
<li>The essence of falling shares is the process of optimistic high growth expectations returning to rationality,which takes time until the cyclical shocks brought by the receding of pandemic are digested.</li>
<li>Mindray’s biggest alpha could be the change brought about by M&amp;A. From the perspective of strategic development, the next jump in valuation is likely to depend on subsequent M&amp;A performance.</li>
</ul>


Mindray withstood the negative impact of pandemic/lockdown and continued to achieve solid growth in 2022H1 amid China's “new infrastructure”  projects and the recovery of overseas demand for routine medical care.
The essence of falling shares is the process of optimistic high growth expectations returning to rationality,which takes time until the cyclical shocks brought by the receding of pandemic are digested.
Mindray’s biggest alpha could be the change brought about by M&amp;A. From the perspective of strategic development, the next jump in valuation is likely to depend on subsequent M&amp;A performance.


Shenzhen Mindray Bio-Medical Electronics (300760.CH) 2022H1 - Waiting for the Next Jump in Valuation